Epidarex Capital
Mary joined Epidarex as an Associate in 2013. She has more than 12 years of experience in the commercialization of early-stage health science technologies. As a business manager with Medical Research Council Technology, she was responsible for the exploitation of intellectual property arising from a number of Medical Research Council research institutes.
She previously worked with the Scottish Enterprise Proof of Concept Programme, building and funding spin-out companies from leading Scottish academic institutions.
Mary currently serves on the board of directors of LUNAC Therapeutics Ltd. She has a Ph.D. in Molecular Biology from the University of Edinburgh.
This person is not in any offices
Epidarex Capital
Epidarex Capital is a leading transatlantic venture capital firm that invests in early-stage, high growth life science opportunities in under-ventured markets. Epidarex funds ground-breaking research, often building companies from scratch, to address large unmet medical needs with solutions that provide significant benefits to patients.